IBS patients would trade years of life for relief, and proven help exists

Key takeaways

• In a 2009 survey of 1,966 people with IBS, respondents said they would give up an average of 25% of their remaining life, about 15 years, to be free of symptoms.
• The American College of Gastroenterology says most people can be diagnosed from their symptom pattern, an exam and a few tests, such as a celiac blood test for those with diarrhea.
• The new Rome V criteria, published in 2026, count belly discomfort as well as pain, and the research version asks for symptoms about three times a month instead of weekly.
• Soluble fiber and low-dose tricyclic antidepressants earned strong recommendations from the college, and a 2020 analysis of 41 trials found that gut-directed talk therapy and hypnotherapy beat comparison care.
• Rectal bleeding, unexplained weight loss, low iron, new symptoms later in life and a family history of colon cancer are reasons to see a clinician before trying self-care.

In 2009, a research team led by Douglas Drossman published a survey of 1,966 adults with irritable bowel syndrome (IBS), most in the U.S. or Canada¹.

The team asked what people would trade for a treatment that made them symptom-free. On average, respondents said they’d give up 25% of their remaining life, roughly 15 years¹. One in seven would accept a 1-in-1,000 chance of dying¹.

They had cut back on normal activities an average of 73 days a year¹. People found the survey through IBS information websites, so they were likely sicker than average. Even so, the numbers show how much IBS can take from a life.

Yet people with IBS often hear that nothing is wrong, or that it’s all in their head.

Here is a map of IBS care, from diagnosis to treatment, with links to our deeper guides.

IBS is real, and normal test results don’t mean it’s in your head

The American College of Gastroenterology (ACG), a professional group of digestive-disease doctors, calls IBS a disorder of gut-brain interaction³. Your gut and brain are tightly wired together, and your brain normally filters out most of the signals your gut sends³.

Stress and hard early-life experiences can change how sensitive the gut is, the ACG says³.

Normal test results are reassuring, the ACG says, and they do not mean your symptoms are “all in your head”³.

The experts who write diagnostic rules agree. Rome V, the new edition of the Rome criteria, renamed “functional bowel disorders” as plain “bowel disorders,” partly because “functional” can feel stigmatizing⁴.

Stigma is still common. A 2020 review of 20 studies in The Lancet Gastroenterology & Hepatology found it tied to worse outcomes². Among its findings:

• Among 496 gastroenterology outpatients, 27% of those with IBS reported moderate to high stigma, compared with 8% of those with inflammatory bowel disease (IBD).
• In a study of 49 patients, 57% felt stigmatized. Nearly a third of those said other people had called their condition all in their head.
• In a survey of 254 nurses in the United Kingdom, 88% agreed that IBS was all in patients’ minds.

If you’ve felt brushed off, you’re not imagining it. Our article on what to say when a doctor isn’t listening offers scripts.

Doctors diagnose IBS from a pattern, and the rules changed in 2026

Doctors diagnose IBS with the Rome criteria, written by an international expert group. Under Rome IV, the version used for the past decade, you need belly pain on average at least one day a week over the past three months⁶⁹.

The pain also has to come with at least two of these three features⁹:

• It’s linked to having a bowel movement.
• It comes with a change in how often you go.
• It comes with a change in how your stool looks.

Symptoms must have started at least six months before diagnosis. Bloating isn’t required⁹.

Your subtype depends on your stools, sorted by the Bristol stool form scale, a seven-point chart from hard lumps (type 1) to watery stool (type 7). Our gut motility article explains it. The subtypes⁹:

• IBS-C (constipation): more than a quarter of abnormal stools are hard (types 1–2), and fewer than a quarter are loose (types 6–7).
• IBS-D (diarrhea): the reverse.
• IBS-M (mixed): more than a quarter of each.
• IBS-U (unclassified): no clear pattern.

In 2026, the Rome Foundation published Rome V⁴⁶. Jan Tack, the foundation’s president, described the main IBS changes in an August 2026 interview⁶:

• Discomfort now counts as well as pain, which he said better fits patients in Asia and Hispanic countries.
• The research version requires symptoms about three times a month, not once a week. The clinical version drops strict counts; bothersome symptoms in the right pattern are enough.
• Pain tied mainly to menstrual periods should prompt a look for endometriosis, and pain that never lets up suggests a different pain disorder.

Wider rules catch more people. A Massachusetts General Hospital team applied each version to 1,275 members of a U.K. IBS registry. Seventy percent met Rome V, compared with 59% for Rome IV⁷. The 108 people who met Rome IV but not Rome V were the sickest: compared with them, the Rome V group had milder symptoms and better quality of life⁷.

That’s one reason IBS numbers swing so widely. A 2021 Rome Foundation study of 73,076 adults in 33 countries found that 4.1% of people surveyed online met Rome IV criteria, and 1.5% of those interviewed at home did⁸. Under the older Rome III rules, the online figure was 10.1%⁸.

A confident diagnosis takes a few tests, not every test

In 2021, the ACG published its first guideline on managing IBS⁹. Its central message on diagnosis: IBS is not whatever is left after every other disease has been ruled out⁹.

Instead, the guideline recommends a positive diagnosis, built on your history, an exam and a few targeted tests⁹. The ACG says this approach gets people to treatment sooner and is more cost-effective⁹.

What the guideline advises on common tests⁹:

Test	ACG advice
Celiac disease blood test	Yes, if you have diarrhea symptoms (strong recommendation)
Fecal calprotectin, a stool test for gut inflammation, plus a C-reactive protein blood test	Suggested with diarrhea and no warning signs, to check for IBD
Stool tests for germs	Not routinely
Colonoscopy under age 45	Not routinely, if you have no warning signs
Food allergy or sensitivity tests	Not routinely; only with reactions that repeat
Tests of the pelvic floor muscles	Suggested if constipation doesn’t respond to standard treatment

Two cautions. The celiac test is accurate only while you’re still eating gluten, as our gut-healing article explains. And colon cancer screening, which the U.S. Preventive Services Task Force advises for average-risk adults from age 45, covers people without symptoms¹⁰. Warning signs call for a diagnostic workup instead.

The first rung: fiber, food and movement

No decision tree yet picks the right IBS treatment for each person; Tack says choosing remains a guided conversation with your clinician⁶. Most plans start with changes you can make yourself.

Soluble fiber. The ACG strongly recommends soluble fiber, such as psyllium, for overall IBS symptoms, but not insoluble fiber such as wheat bran⁹. Start with a small dose and build slowly. Our article on soluble and insoluble fiber explains why the type matters.

A short low-FODMAP trial. FODMAPs are a group of fermentable carbohydrates found in many everyday foods. The ACG recommends a limited trial of a low-FODMAP diet, though it rated the evidence very low quality⁹.

Tack reports that 80% to 85% of patients respond at his center in Belgium⁶. That’s one clinic’s experience, not a trial result. Our companion article covers the trials, the diet’s three phases and why a dietitian helps.

Exercise. In a 2011 Swedish trial, University of Gothenburg researchers asked half of 102 adults with IBS to get 20 to 30 minutes of moderate to vigorous activity three to five times a week¹¹. After three months, symptom scores fell an average of 51 points in the active group and 5 points in the others¹¹.

In 2022, Cochrane, an independent network that pools trial results, reviewed 11 trials with 622 adults. Walking, yoga, qigong and treadmill programs may improve overall symptoms, but the evidence was very low certainty¹². Movement is cheap and healthy anyway, so it belongs on the first rung.

Peppermint oil. The ACG suggests peppermint oil for overall symptoms, rating the evidence low quality⁹. Our article on reading research abstracts walks through a major trial, side effects included.

Probiotics. The ACG suggests against probiotics for overall IBS symptoms, citing very low-quality evidence⁹. Other expert groups disagree, as our gut-healing article explains.

The second rung: treat the gut-brain loop

Gut-directed psychotherapy. This means cognitive behavioral therapy built for IBS, or hypnotherapy aimed at the gut. The ACG suggested it in 2021 for overall symptoms and urged doctors to offer it as part of a full plan, not as a last resort⁹.

A 2020 analysis in the journal Gut pooled 41 randomized trials with 4,072 people. CBT, including self-guided versions, and gut-directed hypnotherapy all beat comparison care, and none clearly beat the others⁵. The authors warned that many trials were at high risk of bias, so the benefit is probably overstated⁵. Our gut-brain article covers a larger 2025 update.

Low-dose tricyclic antidepressants. These drugs include amitriptyline and nortriptyline³. At IBS doses they serve as neuromodulators, medicines that act on nerve signaling, rather than as treatment for depression³¹³. The ACG strongly recommends them for overall IBS symptoms, based on moderate-quality evidence⁹.

The biggest test came from England. In the ATLANTIS trial, published in The Lancet in 2023, 463 adults whose IBS hadn’t responded to first-line care took amitriptyline or a placebo for six months¹³. The dose started at 10 mg at night and could rise to 30 mg¹³. The U.K. government’s National Institute for Health and Care Research paid for it¹³.

People on amitriptyline were nearly twice as likely to report overall relief¹³. But their symptom scores improved only 27 points more than placebo, short of the 35-point change the researchers had set as the smallest meaningful one. The ACG’s reviewer called the benefit modest¹³.

Dry mouth and drowsiness each affected about half of the amitriptyline group. Thirteen percent stopped because of side effects, versus 9% on placebo¹³. And taking one doesn’t mean your IBS is psychological, the ACG says³.

The third rung: prescription drugs matched to your subtype

For IBS-C. The ACG strongly recommends two drugs called guanylate cyclase activators, linaclotide and plecanatide, based on high-quality evidence⁹. It also strongly recommends lubiprostone, a chloride channel activator⁹.

The American Gastroenterological Association (AGA) added tenapanor in 2022, with a conditional recommendation¹⁴. The two groups split on polyethylene glycol (PEG) laxatives. The AGA gives them a conditional nod, while the ACG suggests against them for overall IBS-C symptoms⁹¹⁴.

You may still see tegaserod on IBS-C drug lists, including the ACG’s patient page³. Its maker pulled it from the U.S. market in 2022, calling that a business decision, not a safety or effectiveness one¹⁵.

For IBS-D. The ACG strongly recommends rifaximin, an antibiotic that acts mainly in the gut, and allows up to three courses⁹. Eluxadoline gets a conditional recommendation from both groups⁹¹⁴. The AGA says it shouldn’t be used by people without a gallbladder or by those who have more than three alcoholic drinks a day¹⁴.

Alosetron is reserved for women with severe IBS-D, under a risk-management program¹⁴. Loperamide, sold over the counter, eases diarrhea but doesn’t improve overall IBS symptoms⁹.

Your IBS care map, by subtype

Use this map, our own summary of the guidelines above, to plan a visit, not to treat yourself. Check the warning signs first.

Subtype	First steps to try	Next steps to ask about	Keep in mind
IBS-C	Soluble fiber, started low; regular activity; a dietitian-led low-FODMAP trial if pain or bloating persists	Linaclotide, plecanatide, lubiprostone or tenapanor; gut-directed therapy; pelvic floor testing if nothing helps	One ACG reviewer reserves tricyclics for IBS-D13
IBS-D	Celiac blood test while still eating gluten, plus an inflammation check; soluble fiber; low-FODMAP trial; loperamide for bad days	Rifaximin; a low-dose tricyclic; eluxadoline; alosetron for women with severe symptoms; gut-directed therapy	Eluxadoline isn’t for people without a gallbladder or who drink heavily14
IBS-M	A two-week stool diary to confirm the pattern; soluble fiber; low-FODMAP trial; peppermint oil for pain	Gut-directed therapy; ask whether a constipation or diarrhea treatment fits your most common pattern	The ACG guideline has no IBS-M drug list9

Questions to bring to your clinician:

1. Do my symptoms fit IBS, and which subtype am I?
2. Do I have any warning signs that need tests first?
3. Have I had a celiac blood test, and should I keep eating gluten until I do?
4. Which first step do you suggest, and how long should I try it before we judge it?
5. Can you refer me to a dietitian or a gut-directed therapist?
6. How much better than placebo did this medicine do, what does it cost, and what side effects are common? (Ask the same of any supplement.)

How strong is the evidence?

Approach	Rating	Why
Soluble fiber, such as psyllium	Strong evidence	ACG strong recommendation, moderate-quality evidence9
Short, guided low-FODMAP trial for symptom relief	Strong evidence	Ranked first among diets in pooled trials (see our low-FODMAP article); ACG graded the quality very low9
Gut-directed CBT or hypnotherapy	Strong evidence	Benefit across 41 pooled trials, probably overstated; ACG’s 2021 grade was very low59
Low-dose tricyclic antidepressants	Strong evidence	ACG strong recommendation; a large 2023 trial found a modest benefit913
Linaclotide or plecanatide for IBS-C	Strong evidence	ACG strong recommendation, high-quality evidence9
Rifaximin for IBS-D	Strong evidence	ACG strong recommendation, moderate-quality evidence9
Exercise	Promising but early	One positive trial; Cochrane rated the evidence very low certainty1112
Peppermint oil	Promising but early	ACG conditional suggestion, low-quality evidence9
Probiotics for overall IBS symptoms	Not enough evidence	ACG suggests against them; expert groups disagree9
Fecal transplant for IBS	Evidence says no, or unsafe	ACG strongly recommends against it9

Why rate two approaches higher than the ACG did in 2021? For gut-directed therapy, dozens of randomized trials keep finding benefit⁵. Pooled diet trials say the same for a short low-FODMAP trial, as our low-FODMAP article shows. The ACG graded both very low quality, and the trials have flaws, so expect a smaller benefit in daily life.

Why this map fits natural-health values

Look at the first two rungs: fiber, food, movement and mind-body therapy. Those are tools many natural-health readers already trust. In the 2009 survey, 37% of respondents were already using complementary or alternative treatments¹.

The ACG’s own patient page lists deep breathing, meditation, yoga and acupuncture among options³. The evidence behind each varies, so test one change at a time, with an end date.

Respect for the body also means respect for its warning signs. A gut-healing plan shouldn’t delay a celiac test or a red-flag check. And the skepticism you’d bring to a drug ad belongs in the supplement aisle, too; our companion article rates digestive supplements.

Questions readers ask

The bottom line

IBS is a real disorder of gut-brain interaction, not a diagnosis of last resort and not something imagined. Most people can get a confident diagnosis from their symptom pattern, an exam and a few targeted tests, as long as warning signs are checked first.

Treatment works best as a ladder: soluble fiber, movement and a guided low-FODMAP trial first, then gut-directed therapy or a low-dose neuromodulator, then drugs matched to your subtype. Give each step a fair trial, and bring your questions to a clinician who takes you seriously.

Related reading

• The low-FODMAP diet is a test, not a way to eat forever
• Your gut and brain really talk, but many mood claims started in mice
• Picking a fiber takes more than knowing soluble from insoluble
• Leaky gut can be measured, but most “heal your gut” protocols haven’t been tested
• What to say when a doctor isn’t taking you seriously

Sources

1. Drossman DA, Morris CB, Schneck S, et al. “International Survey of Patients With IBS: Symptom Features and Their Severity, Health Status, Treatments, and Risk Taking to Achieve Clinical Benefit.” Journal of Clinical Gastroenterology, 2009;43(6):541–550 (McMaster University record). experts.mcmaster.ca
2. Hearn M, Whorwell PJ, Vasant DH. “Stigma and Irritable Bowel Syndrome: A Taboo Subject?” The Lancet Gastroenterology & Hepatology, 2020;5:607–615 (copy hosted by the Portuguese Society of Gastroenterology). spg.pt
3. American College of Gastroenterology. “Irritable Bowel Syndrome: Overview.” ACG patient information, updated February 2026. gi.org
4. German Society for Neurogastroenterology and Motility (DGNM). “Rome V Published: New Criteria for Disorders of Gut–Brain Interaction.” Accessed October 2026. neurogastro.de
5. Black CJ, Thakur ER, Houghton LA, Quigley EMM, Moayyedi P, Ford AC. “Efficacy of Psychological Therapies for Irritable Bowel Syndrome: Systematic Review and Network Meta-Analysis.” Gut, 2020;69(8):1441. pubmed.ncbi.nlm.nih.gov
6. Tack J (interviewed; Chey WD, section editor). “Rome V and Irritable Bowel Syndrome.” Gastroenterology & Hepatology, August 2026;22(8):443–446. gastroenterologyandhepatology.net
7. Brunk D. “Rome V Criteria Capture More People With IBS, but a Milder Group” (report on Staller K, et al., Clinical Gastroenterology and Hepatology, 2026). GI & Hepatology News, American Gastroenterological Association, August 20, 2026. news.gastro.org
8. Sperber AD, Bangdiwala SI, Drossman DA, et al. “Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study.” Gastroenterology, 2021;160(1):99–114 (Ben-Gurion University record). pubmed.ncbi.nlm.nih.gov
9. Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B. “ACG Clinical Guideline: Management of Irritable Bowel Syndrome.” American Journal of Gastroenterology, 2021;116(1):17–44 (recommendation summary from MDCalc; ACG Magazine summary; visual summary by T. Hang, Emory University; PubMed abstract). mdcalc.com and webfiles.gi.org and med.aws.emory.edu and pubmed.ncbi.nlm.nih.gov
10. U.S. Preventive Services Task Force. “Colorectal Cancer: Screening.” Final recommendation statement, May 18, 2021. uspreventiveservicestaskforce.org
11. University of Gothenburg. “Exercise Improves Symptoms in Irritable Bowel Syndrome” (on Johannesson E, Simrén M, Strid H, Bajor A, Sadik R, American Journal of Gastroenterology, 2011;106:915–922). ScienceDaily, January 25, 2011. sciencedaily.com
12. Liguori S. “Physical Activity for Treatment of Irritable Bowel Syndrome: A Cochrane Review Summary” (on Nunan D, et al., Cochrane Database of Systematic Reviews, 2022, CD011497). Journal of Rehabilitation Medicine, 2023;55:jrm15761. medicaljournalssweden.se
13. Schoenfeld P. “Low-Dose Amitriptyline for IBS in Primary Care” (review of Ford AC, et al., ATLANTIS trial, The Lancet, 2023;402:1773–1785). Evidence-Based GI, American College of Gastroenterology, December 12, 2023; and University of Leeds news release, October 2023. gi.org and medicinehealth.leeds.ac.uk
14. Guideline Central. “2022 AGA Guidelines on the Pharmacological Management of IBS-C and IBS-D” (summary of American Gastroenterological Association guidelines). September 20, 2022. guidelinecentral.com
15. Managed Healthcare Executive. “Alfasigma Withdraws Zelnorm From Market.” June 30, 2022. managedhealthcareexecutive.com